Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03266653 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v14
  2. Primary completion date: Aug 31, 2024 to Dec 31, 2025
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v13
  3. Study completion date: Dec 31, 2024 to Dec 31, 2025
    • Site contacts updated at 1 of 8 sites
    v12
  4. Eligibility criteria revisedv11
  5. Primary completion date: Aug 31, 2023 to Aug 31, 2024
    • Study completion date: Dec 31, 2023 to Dec 31, 2024
    • Collaborators: 2 to 7
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 6 to 8v9
  2. Primary completion date: Dec 31, 2021 to Aug 31, 2023
    • Study completion date: Dec 31, 2022 to Dec 31, 2023
    v8
  3. Study sites: 4 to 6v7
  4. Re-verified, no change to tracked fieldsv6
  5. Primary completion date: Dec 31, 2020 to Dec 31, 2021
    • Start date: Oct 1, 2018 to Jul 7, 2020
    • Study completion date: Dec 31, 2021 to Dec 31, 2022
    • Eligibility criteria shortened, about 91 words
    v5
  6. Study sites: 3 to 4v4
  7. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 1, 2018 to Oct 1, 2018
    • Site details revised at 3 of 3 sites
    v3
  8. Start date: Oct 1, 2017 to May 1, 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Trial Details
NCT Number NCT03266653
Lead Sponsor New York Medical College
Collaborators: Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Indiana University, Washington University School of Medicine, University of California, Los Angeles, University of California, San Francisco
Conditions
(from sponsor)		 Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Related terms Epstein-Barr Virus Infections, Primary Immunodeficiency Diseases
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov